Silhueta de pessoa indiferenciada

Wolfgang Alexander Link

Professor auxiliar convidado
Faculdade de Medicina e Ciências Biomédicas
Docentes Universitário
CT em Funções Públicas a termo resolutivo certo
Dr Link is a CSIC researcher at Institute of Biomedical Research Alberto Sols (Madrid) focused on drug resistance mechanisms in cancer. He is also group leader at the Algarve Biomedical Center Research Institute (ABC-RI), and holds a position as an invited assistant professor at the Faculdade de Medicina e Ciências Biomédicas (FMBC) at the Universidade do Algarve (UAlg) in Faro and professor honorário at the Universidad Autónoma, Madrid (UAM). He is co-founder of Refoxy Pharma GMBH, Berlin/Boston, a biotech company dedicated to target FOXO proteins ( Dr Link counts with more than 25 years of experience in basic and translational biomedical research. He holds three patents (one licensed to Sanofi), published three books, three book chapters and over 90 articles (4 more under revision), 11 as first author, over 40 as senior author. He published articles (selection) in Nature, Oncogene, PNAS, Nature Reviews Drug Discovery, Trends in Biotechnology, EMBO J, The Lancet Oncology, Trends in Pharmacological Sciences, Drug Resistance Updates and Aging Cell. His work has been cited 6478 times. He also serves as an editorial board member of prestigious, international peer reviewed journals including Cancers, Frontiers in Oncology and Frontiers in Cell and Developmental Biology. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019). Dr Link acts as an expert evaluator for funding organisations including ERC (EU), The Brain Tumour Charity (UK), Leuka (UK), Dutch Cancer Society (Netherlands), Austrian Science Fund (ASF, Austria), ANEP (Spain), FCT (Portugal), MOH, AIFA (Italy), University of Macau (China), HRC (New Zealand). He also serves as a peer-reviewer for (selection) Carcinogenesis, Chemical Reviews, Drug Discovery Today, FEBS Letters, Hepatology, International Journal of Cancer, J Cell Science, Nature Chemical Biology, Nature Comm., Oncogene, PloS ONE, PNAS, Scientific Reports, Trends in Cell Biology. Importantly, the Link group was one of the first to identify CRM1 inhibitors and ever since was on the forefront of CRM1 drug discovery. He identified TRIB2 as an oncogene involved in therapy resistance. Dr Link obtained his PhD degree from the University of Hamburg, followed by a postdoc at CNB, Madrid before joining the pharma company EleGene AG (Germany) as a senior scientist. In 2001, he moved to Madrid joining the newly-founded CNIO where he was promoted to head the screening group in 2010. In 2012, he accepted a position as an assistant professor at the UAlg, Faro, Portugal where he was head of the Department of Oncobiology and director of the Masters program on Molecular mechanisms of cancer. In 2018, he also joined the Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM) in Madrid, Spain as a CSIC researcher and group leader. Five greatest contributions to science: 1. Cloning of Arg3.1/ARC, one of the most important genes in neuroscience and synaptic plasticity (Proc. Natl. Acad. Sci. USA 92, 5734-5738. doi: 10.1073/pnas.92.12.5734) 2. Cloning of DREAM, the first transcription factor directly regulated by calcium (Nature, 398, 80-84. doi: 10.1038/18044) 3. Identifying genetic and pharmacological means to activate FOXO transcription factors considered as key tumor suppressors and longevity genes (Nature Reviews Drug Discovery 20, 21-38. doi: 10.1038/s41573-020-0088-2) 4. Characterizing TRIB2 as an oncogene in Melanoma that confers therapy resistance (Nature Comm. 8, 14687. doi: 10.1038/ncomms14687) 5. Generating high content screening (HCS) technology to identify CRM1 inhibitors (Trends Biotechnol. 28, 237-245. (Title story + Cover art) doi: 10.1016/j.tibtech.2010.02.005)


2022/12/16 - 2022/12/16. Organização de evento. Online Panel Discussion with Vera Gorbunova (USA)
and Joris Deelen (Germany), Decoding the genetic secrets
of extreme longevity. December 16th, 2022
2022/09/29. Apresentação oral de trabalho. High content imaging-based discovery of novel targets and small molecule compounds for healthy aging and anticancer therapy. (Invited talk). Jornada de usuarios de High Content Screening, 29th September 2022 at Instituto de Salud Carlos III, Centro Nacional de Microbiología, Majadahonda, Spain.
2022/06/29 - Presente. Organização de evento. Webinar with Robert A. Weinberg (USA)
Whitehead Institute for Biomedical Research
with over 300 participants
29 June 2022
2022/06/27. Apresentação oral de trabalho. Understanding and Targeting the TRIB2-AKT-FOXO axis in human cancer and aging. III International Meeting of the Portuguese Society of Genetics, 27th and 28th June 2022 at the University of Évora, Portugal.
2021/09/06. Apresentação oral de trabalho. Emerging targets and small molecule drug candi-dates to overcome cancer therapy resistance, Invited talk, STRATAGEM, Annual conference 6th September 2021, Prague, Czech Republic. STRATAGEM, Annual conference. STRATAGEM (Prague, República Checa).
2020/04/01 - 2021/03/31. Orientação. Generation of drug resistant cell lines as a model to study melanoma, pancreatic cancer and glioblastoma.. Orientador de Inês Grenho .
2019/09/01 - 2021/01/29. Orientação. Descoberta de moduladores de FOXO para tratamentos
anticancerígenos e antienvelhecimento
.Master . Coorientador.
2021/01/07. Apresentação oral de trabalho. HTVS protocol to identify non-covalent inhibitors of CRM1, João Gonçalo Nunes Sequeira *, Wolfgang Link, Miguel Machuqueiro, MOL2NET'21, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 7th ed., Chem-Bioinformatics Congress München, Germany-Chapell Hill, USA, 2021.
2010/01/01 - 2020/12/31. Outro júri / avaliação. JOURNAL REVIEWER FOR:

Oxidative Medicine and Cellular Longevity, PloS ONE, PNAS, Redox Biology, Rejuvenation Research, Scientific Reports, SpringerPlus, Targeted Oncology, Trends Cell Biology, WJBC, World Journal of Medicine and Medical Science Research
2020/04/22. Apresentação oral de trabalho. Tribbles pseudokinases in anti-cancer therapy resistance . International Web Symposium, Pseudokinases and Tribbles - from Molecules to Therapy. Helmholtz Zentrum München, Germany (Madrid, Espanha).
2010/01/01 - 2020/03/31. Outro júri / avaliação. JOURNAL REVIEWER FOR:

Analytical Chemistry, Apoptosis, BBA - Molecular Basis of Disease, Biochemical J., Biotechniques, Biotechnology J, BMC Cell Biology, Cancer Drug Resistance, Carcinogenesis, ChemBioChem, Chemical Research in Toxicology, Chemical Reviews, Cellular Signalling, Current Medicinal Chemistry, Current Molecular Medicine, Cytometry A, Drug Discovery Today, EBioMedicine, European Journal of Pharmacology, Expert Opinion On Drug Discovery, F1000_Faculty Reviews, FEBS Letters, Gene, Gynecologic Oncology, Hepatology.
2010/01/01 - 2020/03/31. Outro júri / avaliação. JOURNAL REVIEWER FOR:

International Journal of Cancer, Internat J Developmental Neurosci, International Journal of Oncology, J Biomol Screening, J Cell Biochem, J Cell Science, J Gastrointestinal and Liver Diseases, J Hematology & Oncology, J Inorg Biochem, Journal of Visualized Experiments, Life Sciences, Medical Research Reviews, Micromachines, Molecular Biology Reports, Molecular Imaging, Molecules, Nature Chemical Biology, Nature Comm., Neoplasia, Neuroscience Letters, Oncogene, Oncology Letters, Oncology Reports, Oncotarget, Oral Oncology.
2020/02/28. Apresentação oral de trabalho. Targeting FOXO proteins to extend lifespan and fight cancer and anti-cancer drug resistance
Invited talk, STRATAGEM, Annual conference 28th February 2020, Belgrade, Serbia. STRATAGEM, Annual conference. COST (Belgrade, Sérvia).
2020/01/31. Apresentação oral de trabalho. Spinning off academic discovery of FOXO - modulating compounds into small biotech companies. TRANSAUTOPHAGY Translational Workshop. COST (Faro, Portugal).
2020/01/30 - 2020/01/31. Organização de evento. 2nd Joint WG4-WG5 TRANSAUTOPHAGY, Faro/Portugal

2020/01/15. Apresentação oral de trabalho. Harmine and Piperlongumine revert TRIB2-mediated drug resistance. Invited talk. International Online Symposium on Synthesis and nanodelivery strategies for new therapeutic tools against Multidrug Resistant Tumours. COST STRATAGEM (Madrid, Espanha).
2019/10/01 - Presente. Comissão de avaliação. TubInTrain Member of the international Evaluation Board of TubInTrain, European Joint Doctorate on chemistry and biology and focused on the microtubules breakdown (
Consultoria / Parecer. Expert advisor for European FET
Expert, Trendington; Prefet. Defining topics for European FET call
2019/09/20. Apresentação oral de trabalho. Targeting the TRIB2 - FOXO axis of anti-cancer drug resistance; September 20, Invited Talk at General, Hospital of Vienna, Austria.. Stratagem WG meeting. General Hospital of Vienna (Vienna, Áustria).
2019/06/07. Apresentação oral de trabalho. Targeting FOXO proteins to fight cancer and extend lifespan; IIBM seminar, June 7, Madrid, Spain . Seminar Cycle. IIBM (Madrid, Espanha).
2019/04/12. Apresentação oral de trabalho. Tribbles proteins determine the level of activity of the oncokinase AKT. Jornadas Liga Portuguese Contra o Cancro. Liga Portuguese Contra o Cancro, IPOLFG (Lisbon, Portugal).
2019/03/26. Apresentação oral de trabalho. High content screening-based discovery of natural products from microalgae to treat cancer and slow aging, I Seminário Projeto ALGARED+, March 26, Faro, Portugal. Seminário Projeto ALGARED+. CCMAR (Faro, Portugal).
2018/12/13. Apresentação oral de trabalho. Targeting FOXO proteins to fight cancer and extend lifespan. “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” Conference, December 13, 2018, La Laguna, Tenerife, Spain . Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” Conference. COST (tenerife, Espanha).
2018/10/16. Apresentação oral de trabalho. TRIB2-mediated activation of AKT confers resistance to anti-cancer therapy, International workshop on The cell biology behind the ONCOGENIC PIP3 LIPIDS October 16, 2018, Baeza, Spain. International workshop on “The cell biology behind the ONCOGENIC PIP3 LIPIDS. Universidad Internacional de Andalucía - Sede Antonio Machado de Baeza (Baeza, Espanha).
2018/09/21 - 2018/09/22. Arbitragem científica em conferência. SINAL, 9th Meeting on Signal Transduction . SINAL.
2017/09/01 - 2018/06/30. Orientação. Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK . Orientador.
2018/05/29. Apresentação oral de trabalho. Targeted strategies for the discovery of chemical compounds with therapeutic potential against cancer, Universidad de La Laguna, Instituto de Productos Naturales y Agrobiología del CSIC, May 29,2018, Tenerife, Spain. Seminar. Universidad de La Laguna, Instituto de Productos Naturales y Agrobiología del CSIC (La laguna, Espanha).
2018/05/08. Apresentação oral de trabalho. TRIB2 acts as a major driver of tumorigenesis and anti-cancer drug resistance. 2th International Symposium on “TRIBBLES and Diseases". TRIBBLES Network (Beijing, China).
2018/04/18. Apresentação oral de trabalho. Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitors in the context of melanoma. III Jornadas Liga Portuguese Contra o Cancro. Liga Portuguese Contra o Cancro (Lisbon, Portugal).
2018/03/03. Apresentação oral de trabalho. Targeted drug discovery for Precision Oncology
. 5th MC/WG Meeting. COST Action CM1407 (Salini Resort, Malta).
2016/09/01 - 2017/10/15. Orientação. Study of the TRIB2 protein network . Orientador.
2017/06/06. Apresentação oral de trabalho. Characterization of TRIB2 mediated resistance to anti-melanoma drugs . II Jornadas de Investigação em Oncologia em Portugal. IPOLFG (Lisbon, Portugal).
2017/05/19. Apresentação oral de trabalho. Means to restore tumor suppressor genes in pancreatic cancer. 2nd Porto Precision OONCOLOGY Meeting. IPATIMUP (Porto, Portugal).
2017/05/08. Apresentação oral de trabalho. TRIB2, FOXO and p53: The evil axis of anti-cancer drug resistance. 8th Meeting on Signal Transduction. SINAL (Lisbon, Portugal).
2017/04/01 - Presente. Orientação. Characterizing the role of FOXO regulators and FOXO isoforms in cancer. Coorientador.
2017/03/03. Apresentação oral de trabalho. FOXO Caught in the Crosshairs: Discovering Targets and Drugs for Innovative Anti-Cancer Therapies . COST Annual Meeting. Jagiellonian University (Krakow, Polónia).
2016/10/06. Apresentação oral de trabalho. TRIB2, FOXO and p53: The evil axis of anti-cancer drug resistance . Invited seminar. University of Sheffield, Medical School, Sheffield (Sheffield, Reino Unido).
2016/06/18. Apresentação oral de trabalho. FOXO Caught in the Crosshairs: Strategies of Innovative Drug Discovery . Invited Seminar. CCMAR (faro, Portugal).
2016/06/08 - 2016/06/09. Organização de evento. International Meeting: ¿Tribbles Proteins at the Interface of Metabolism and Cancer (2016). Universidade do Algarve - Campus de Gambelas.
2016/06/08. Apresentação oral de trabalho. TRIB2 as an oncogenic FOXO suppressor protein . Tribbles Proteins at the Interface of Metabolism and Cancer. TRIBBLES network (Faro, Portugal).
2016/04/04. Apresentação oral de trabalho. Discovering ways to tackle cancer drug resistance
. Invited seminar. IIBM-CSIC (Madrid, Espanha).
2016/02/12. Apresentação oral de trabalho. TIBBLES breaking bad: TRIB2 confers resistance to anti-cancer drugs . Invited seminar. IdiPAZ Madrid (Madrid, Espanha).
2014/09/01 - 2015/07/04. Orientação. Characterization of TRIB2 following PI3K inhibition. Orientador.
2014/09/01 - 2015/06/30. Orientação. Characterization of TRIB2-mediated resistance to anti-cancer drugs. Orientador.
2014/09/01 - 2015/06/30. Orientação. TRIB2 confers resistance to MAPK and mTOR1 inhibitors. Orientador.
2015/04/23. Apresentação oral de trabalho. TRIB2 acts as an oncogene in melanoma and confers drug resistance by deregulating the AKT signalling network
. Biochemical Society Conference, Tribbles at the crossroads of metabolism, cancer, immunity and development. Biochemical Society (Budapest, Hungria).
2014/10/14. Apresentação oral de trabalho. Translocation in Cancer Therapy . CIBICAN Conference on Molecular Pharmacology and Mechanisms of New Anticancer Drugs. CIBICAN (Tenerife, Espanha).
2013/09/01 - 2014/06/30. Orientação. Investigating the role and function of Tribbles 2 (TRIB2) in drug resistance within cancer. Orientador.
2013/07/05. Apresentação oral de trabalho. Targeting the subcellular localization of tumor suppressors and oncogenic proteins as anti-cancer therapy . Invited seminar. Fundación Medina, University of Granada (Granada, Espanha).
2013/06/21. Apresentação oral de trabalho. FoxO Proteins as Potential Targets for Anti-Cancer Therapy . FOXO3 and Related Transcription Factors in Development, Aging and Exceptional Longevity. Longevity Consortium, US (San Francisco, Estados Unidos).
2012/07/04. Apresentação oral de trabalho. Exploring the spatio-temporal regulation of disease-relevant proteins for the development of anti-cancer therapies . Invited Seminar. Universita degli Studi di Milano (Milan, Itália).
2012/04/14. Apresentação oral de trabalho. Exploring the spatio-temporal regulation of disease-relevant proteins for the development of anti-cancer therapies
. SINAL2012, 6th National Meeting on Cell Signaling, University of Minho. SINAL (Braga, Portugal).
2012/03/16. Apresentação oral de trabalho. Protein localization in disease and therapy . 3rd Scientific Meeting of Institute for Biotechnology and Bioengineering Instituto Superior Técnico. Instituto Superior Técnico (Lisbon, Portugal).
2012/03/11 - Presente. Outro júri / avaliação. EVALUATION FOR RESEARCH FUNDING ORGANISATIONS
Austrian Science Fund (ASF, Austria)
Dutch Cancer Society (Netherlands)
European Research Council (European Union)
FCT and Fundo iMM Laço (Portugal)
Health Research Council New Zealand
Italian Ministry of Health and Agenzia Italina del Farmaco (Italy)
North West Cancer Research, Leuka and the Brain Tumour Charity (UK)
Spanish Agency of Evaluation and Assessment (Spain)
University of Cape Town (South Africa)
University of Macau (China)
2012/03/01 - Presente. Outro júri / avaliação. PARTICIPATION IN INTERNATIONAL NETWORKS

COST Action: CM1106, Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells

COST Action: BM1204, An integrated European platform for pancreas cancer research: from
basic science to clinical and public health interventions for a rare disease

COST Action: CM1407, Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery

Longevity Consortium, US (
2011/07/07. Apresentação oral de trabalho. Protein localization in disease and therapy . Invited seminar. nstitute for Biotechnology Bioengineering Dep. Ciências Biomédicas e Medicina, Universidade do Algarve (Faro, Portugal).
2011/06/14. Apresentação oral de trabalho. Exploring the spatio-temporal regulation of disease-relevant proteins for the development of therapeutic strategies . Invited seminar. Institut de Recerca, Hospital Universitari Vall d'Hebron.
2011/05/24. Apresentação oral de trabalho. Pathway-oriented target and drug discovery for anticancer therapy

. Invited seminar. UKE Eppendorf, University Hamburg (Hamburg, Alemanha).
2011/05/17. Apresentação oral de trabalho. Mislocalization and therapeutic restoration of normal protein localization in human diseases . BD Biosciences Meeting. University Heidelberg (Heidelberg, Alemanha).
2010/10/04 - 2010/10/05. Organização de evento. BD Pathway Users Workshop (2010).
2010/06/24. Apresentação oral de trabalho. High content imaging-based discovery of novel targets and small molecule inhibitors for anticancer therapy
. 2nd Annual Cellular Imaging Analysis,. Trinity College (Dublin, Irlanda).
2010/02/11. Apresentação oral de trabalho. Image based pathway analysis of FOXO regulation leads to the discovery of therapeutic targets and small molecule inhibitors for anticancer therapy . 22nd Lorne Cancer Conference. Lorne Cancer (Lorne, Austrália).
2009/10/21. Apresentação oral de trabalho. A hierarchical network of image based screens and counter screens to explore strategies for restoring FOXO activity in human cancer. 5th annual Global Imaging Summit. Global Imaging (Berlin, Alemanha).
2009/06/22. Apresentação oral de trabalho. Exploring the Biological Space of FOXO Transcription Factors: Discovery of Kinase Inhibitors for Anticancer Therapy . BIT's Annual World Cancer Congress. BTI (Beijing, China).
2005/12/01 - 2009/05/08. Orientação. Development of Technological Platforms for the identification of Novel Cellular Modulators of FOXO activity

. Orientador de Fábian Zanella de Sá.
2009/01/01 - Presente. Outro júri / avaliação. JOURNAL REVIEWER FOR (selected list)
Biochemical J., Cancers, Carcinogenesis, ChemBioChem, Chemical Reviews, Current Medicinal Chemistry, Current Molecular Medicine, Drug Discovery Today, European Journal of Pharmacology, FEBS Letters, Frontiers in Immunology, Hepatology, J Cell Biochem, J Cell Science, J Cellular and Molecular Medicine, Medical Research Reviews, Nature Chemical Biology, Nature Comm., Neoplasia, Oncogene, Oncology Letters, Oral OncologyPloS ONE, PNAS, Redox Biology, Scientific Reports, Theranostics, Trends Cell Biology
2008/09/10. Apresentação oral de trabalho. Large-scale cell biology – Tackling the complexity of biological systems . Invited Seminar. Centro Nacional de Investigaciones Cardiovasculares (CNIC) (Madrid, Espanha).
2008/08/02. Apresentação oral de trabalho. Using High Content Cellular Imaging to crack the FOXO Code . 4th annual Global Imaging Summit. GIS (cologne, Alemanha).
2008/07/09. Apresentação oral de trabalho. Hunting with the Fox – Loss of Function screen identifies suppressors of FoxO function
. Informa´s MicroRNA & RNAi Industry Summit. Informa (London, Reino Unido).
2008/06/12. Apresentação oral de trabalho. Screening for Content - Image-based Anticancer Drug Discovery . BIT's Annual World Cancer Congress. BIT (Shanghai, China).
2008/03/11. Apresentação oral de trabalho. Cellular pathway analysis using High-Content Imaging. Informa´s 2nd annual High Content Analysis. Informa (berlin, Alemanha).
2008/03/06. Apresentação oral de trabalho. High-Content Screening of complex RNAi and Compound libraries
. Invited seminar. University of Bergen (Bergen, Noruega).
2008/02/05. Apresentação oral de trabalho. Screening for Content - Image-based Anticancer Drug Discovery . Personalised Medicine Partnerships in Oncology & Cardiology. Next Level Pharma (Munich, Alemanha).
2008/01/09. Apresentação oral de trabalho. Chemical genetic approach to study the regulation of nuclear-cytoplasmic shuttling of FoxO using High-Content Imaging
. CHI´s Fifth Annual High Content Analysis. CHI (San Francisco, Estados Unidos).
2007/06/29. Apresentação oral de trabalho. Applying the Power of High Content Screening to Anti-Cancer Drug Discovery . Invited Seminar. Centro de Investigación Príncipe Felipe (CIPF).
2007/06/27. Apresentação oral de trabalho. High Content Screening-based Drug Discovery . Informa´s High Content Analysis. Informa (Vienna, Áustria).
2007/06/08. Apresentação oral de trabalho. An image-based approach to screen for inhibitors of the PI3K/Akt signaling pathway . X Congreso de la Sociedad Ibérica de Citometría (SIC). Sociedad Ibérica de Citometría (valencia, Espanha).
2007/03/26 - 2007/03/27. Organização de evento. High Content Analysis, Spain, 2007 (2007). Centro Nacional de Investigaciones Oncológicas.
2006/10/01 - Presente. Curso / Disciplina lecionado. Lecturer, PhD Course, University of Valencia (UV)
Co-cordinator, Course on high content imaging, CNIO/Madrid
Lecturer, Master Biotechnology, University of Barcelona (UB)
Lecturer, ANGIOKEM, Rhodes, Greece
Lecturer, Master Biotechnology, (UB)
Lecturer, Master Biomedicine, UAlg
Professor, Problem-based learning Medicine, UAlg
Lecturer, Undergraduate Courses in Human genetics, UAlg
Co-coordinator, Master Course Oncobiology, UAlg
Lecturer, Signal Transduction, Cancer Therapy, Master Course, UAlg
Lecturer, ESCCA Summer School (UV)
2006/09/29. Apresentação oral de trabalho. Pathway specific anti-cancer drug discovery: Identification of therapeutic targets associated with PI3K/Akt signalling. . Screening Europe. SEN (Prague, República Checa).
2006/09/26. Apresentação oral de trabalho. Applying the Power of High Content Screening to Anti-Cancer Drug Discovery . Invited Seminar. Institute for Research in Biomedicine (IRB) (Barcelona, Espanha).
2004/09/22. Apresentação oral de trabalho. Development of cell - based high throughput assays targeting the PI3´K/Akt pathway for anti-cancer drug discovery

. III jornadas oncológicas CIC Apoptosis y Cáncer. CIC (Salamanca, Espanha).
2003/09/06. Apresentação oral de trabalho. Day-Night changes in DREAM activity contribute to circadian gene expression in pineal gland. X Congreso de la Sociedad Española de Neurosciencias. Sociedad Española de Neurosciencias (Lerida, Espanha).
Consultoria / Parecer. Expert advisor for pharmaceutical industry

Supervisor, Analysis of PI3K mutants for Eli Lilly, Indianapolis, EE UU

Advisor, Consulting for Consorcio NanoFarma de vehiculización de fármacos (Drug delivery), project
CENIT, Spain

Advisor, Consulting for Bayer Pharma AG targeting Drug Resistance in Cancer

Advisor, Apollo Ventures, funding anti-aging companies


2019/09 - 2021/09. Targeting TRIB2-mediated drug resistance in melanoma (RESIST).
2020/12/01 - Presente. Developing small molecule FOXO activator compounds to treat age-related diseases and promote healthy aging. Orientador.
2019/09 - 2020/08. Superar la resistencia a medicamentos en glioma.
2017/09/01 - 2020/08/31. TRIBBLES. Orientador. Universidade do Algarve - Campus de Gambelas.
2019/04 - 2020/03. Using natural products from regional grapes/wine capable of regulating FOXO factors as potential anti-aging drugs.
2019/04/01 - 2020/03/31. Using natural products from regional grapes/wine capable of regulating FOXO factors as potential anti-aging drugs. Investigador responsável.
2017/09/01 - 2020/03/31. RED transfronteriza para el desarrollo de productos innovadores con microALGAs. Investigador responsável.
2018/12/01 - 2019/11/30. Characterization of therapy-induced stabilization of the drug resistance protein TRIB2. Investigador responsável. Consejo Superior de Investigaciones Científicas.
2017/02/01 - 2018/01/31. Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma. Investigador responsável.
2015/06/01 - 2016/05/31. Role of TRIB2 in the progression of Breast Cancer, Bolsa Laço. Investigador responsável. Universidade do Algarve - Campus de Gambelas.
2014/03 - 2015/02. Impact of FOXO activators on aging.
2014/03/01 - 2015/02/28. Impact of FOXO activators on aging. Investigador responsável.
2013/04 - 2014/03. The role of tribbles homolog 2 (TRIB2) in drug resistance (e.g. to BAY 80-6946, and BAY 1082439, BAY 1001931 and BAY 86-9766) andits potential use as a biomarker to predict resistance to PI3K/Akt and MEK inhibitors.
2006/09/01 - 2009/08/31. Identificación de compuestos líder y dianas terapéuticas: Utilización de la vía de PI3K/Akt para el descubrimiento de compuestos anticancerígenos. Investigador responsável.
2002/03/01 - 2005/02/28. Desarrollo de ensayos celulares basados en la vía PI3’K/Akt para el descubrimiento de moléculas líder con potencial antitumoral. Investigador responsável.


De Sousa-Coelho, Ana Luísa; Gacias, Mar; O'Neill, Brian T.; Relat, Joana; Link, Wolfgang; Haro, Diego; Marrero, Pedro F.. 2023. "FOXO1 represses PPARa-Mediated induction of FGF21 gene expression". Biochemical and Biophysical Research Communications, 644: 122-129.
Passirani, Catherine; Vessières, Anne; La Regina, Giuseppe; Link, Wolfgang; Silvestri, Romano. 2022. "Modulating undruggable targets to overcome cancer therapy resistance". Drug Resistance Updates, 60.
Lucia Jimenez; Carlos Amenabar; Victor; Thomas A. Mackenzie; Carmen Ramos; Andreia Silva; Giampaolo Calissi; et al. 2022. "mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity". Molecules.
Jimenez, Lucia; Mayoral-Varo, Victor; Amenábar, Carlos; Ortega, Judit; Sequeira, João G. N.; Machuqueiro, Miguel; Mourato, Cristiana; et al. 2022. "Multiplexed cellular profiling identifies an organoselenium compound as an inhibitor of CRM1 -mediated nuclear export". Traffic, 23 (12): 587-599.
Orea-Soufi, Alba; Paik, Jihye; Bragança, José; Donlon, Timothy A.; Willcox, Bradley J.; Link, Wolfgang. 2022. "FOXO transcription factors as therapeutic targets in human diseases". Trends in Pharmacological Sciences, 43 (12): 1070-1084.
De Sousa-Coelho, Ana Luísa; Aureliano, Manuel; Fraqueza, Gil; Serrão, Gisela; Gonçalves, João; Sánchez-Lombardo, Irma; Link, Wolfgang; Ferreira, Bibiana I.. 2022. "Decavanadate and metformin-decavanadate effects in human melanoma cells". Journal of Inorganic Biochemistry, 235.
Giampaolo Calissi; Eric W.-F. Lam; Wolfgang Link. 2021. "Therapeutic strategies targeting FOXO transcription factors". Nature Reviews Drug Discovery.
Pérez-Beltrán, Christian Hazael; García-Guzmán, Juan José; Ferreira, Bibiana; Estévez-Hernández, Osvaldo; López-Iglesias, David; Cubillana-Aguilera, Laura; Link, Wolfgang; et al. 2021. "One-minute and green synthesis of magnetic iron oxide nanoparticles assisted by design of experiments and high energy ultrasound: Application to biosensing and immunoprecipitation". Materials Science and Engineering: C.
Bibiana I. Ferreira; Bruno Santos; Wolfgang Link; Ana Luísa De Sousa-Coelho. 2021. "Tribbles Pseudokinases in Colorectal Cancer". Cancers, 13 (11): 2825-2825.
Victor Mayoral-Varo; Lucía Jiménez; Wolfgang Link. 2021. "The Critical Role of TRIB2 in Cancer and Therapy Resistance". Cancers.
Mónica T. Fernandes; Victor Yassuda; José Bragança; Wolfgang Link; Bibiana I. Ferreira; Ana Luísa De Sousa-Coelho. 2021. "Tribbles Gene Expression Profiles in Colorectal Cancer". Gastrointestinal Disorders, 3 (4): 218-236.
Link, Wolfgang; Ilardi, Gennaro; Zannetti, Antonella. 2021. "Editorial: Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression". Frontiers in Oncology, 11.
Jimenez, Lucia; Silva, Andreia; Calissi, Giampaolo; Grenho, Inês; Monteiro, Rita; Mayoral-Varo, Victor; Blanco-Aparicio, Carmen; et al. 2021. "Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3". The Journals of Gerontology: Series A.
Faleiro, Inês; Roberto, Vânia Palma; Demirkol Canli, Secil; Fraunhoffer, Nicolas A.; Iovanna, Juan; Gure, Ali Osmay; Link, Wolfgang; Castelo-Branco, Pedro. 2021. "DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study". Cancers, 13 (24).
Link, Wolfgang. 2020. "CRISPR/Cas9-mediated genome editing: From basic research to translational medicine". Journal of Cellular and Molecular Medicine.
Machado S; Andreia Silva; Ana Luísa De Sousa-Coelho; Isabel Duarte; Inês Grenho; Bruno Santos; Victor Mayoral-Varo; et al. 2020. "Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance". Cancers.
2020. Refoxy Pharmaceuticals GMBH, Berlin/Boston. Drug Discovery.
Ferreira, Bibiana I.; Cautain, Bastien; Grenho, Inês; Link, Wolfgang. 2020. "Small Molecule Inhibitors of CRM1". Frontiers in Pharmacology, 11.
Link, W.. 2019. Introduction to FOXO biology. Vol. 1890.
Barradas, M.; Link, W.; Megias, D.; Fernandez-Marcos, P.J.. 2019. High-throughput image-based screening to identify chemical compounds capable of activating FOXO. Vol. 1890.
Machado, S.; Raposo, C.; Ferreira, B.I.; Link, W.. 2019. Image-based identification of chemical compounds capable of trapping FOXO in the cell nucleus. Vol. 1890.
Link, W.. 2019. Preface. Vol. 1890.
Wolfgang Link. 2019. FOXO Transcription Factors. Editado por Wolfgang Link. Springer New York.
Henriques, V.; Machado, S.; Link, W.; Ferreira, B.I.. 2019. Monitoring the transcriptional activity of FOXO transcription factors by analyzing their target genes. Vol. 1890.
Raposo, Catarina Martins. 2019. "Study of the TRIB2 protein network". Mestrado.
Cui, Bing; Eyers, Patrick A.; Dobens, Leonard L.; Tan, Nguan Soon; Mace, Peter D.; Link, Wolfgang; Kiss-Toth, Endre; et al. 2019. "Highlights of the 2nd international symposium on tribbles and diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer".
Link, Wolfgang. 2019. Principles of Cancer Treatment and Anticancer Drug Development.
Henriques, V.; Martins, T.; Link, W.; Ferreira, B.I.. 2018. "The emerging therapeutic landscape of advanced melanoma". Current Pharmaceutical Design, 24 (5): 549-558.
Link, W.. 2018. "Knowledge-based drug discovery intensifies private appropriation of publicly financed research". The Lancet Oncology, 19 (8): 1017-1018.
Wolfgang Link; Pablo J. Fernandez-Marcos. 2017. "FOXO transcription factors at the interface of metabolism and cancer". International Journal of Cancer, 141 (12): 2379-2391.
Link W. 2017. "Immunology: Mind the immuno-connection gap.".
Hill R; Madureira PA; Ferreira B; Baptista I; Machado S; Colaço L; Dos Santos M; et al. 2017. "TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.".
Ferreira, B.I.; Lie, M.K.; Engelsen, A.S.T.; Machado, S.; Link, W.; Lorens, J.B.. 2017. "Adaptive mechanisms of resistance to anti-neoplastic agents". MedChemComm, 8 (1): 53-66.
Henriques, Vanessa Mendes. 2017. "Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK". Mestrado.
Martins R; Lithgow GJ; Link W. 2016. "Long live FOXO: unraveling the role of FOXO proteins in aging and longevity.".
Cautain B; Castillo F; Musso L; Ferreira BI; de Pedro N; Rodriguez Quesada L; Machado S; et al. 2016. "Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling.".
Santos, Marta Machado Pereira dos. 2016. "Characterization of TRIB2-mediated resistance to anti-cancer drugs". Mestrado.
Silva, Neuton Pedro Gorjão da. 2016. "TRIB2 confers resistance to MAPK and TOR1 inhibitors". Mestrado.
Florindo, Claudia; Ferreira, Bibiana I; Serrão, Sónia M; Tavares, Álvaro A; Link, Wolfgang. 2016. "Subcellular Protein Localisation in Health and Disease". Em eLS, 1-7. John Wiley & Sons, Ltd.
Tarrado-Castellarnau M; Cortés R; Zanuy M; Tarragó-Celada J; Polat IH; Hill R; Fan TW; Link W; Cascante M. 2015. "Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.".
Hill R; Kalathur RK; Colaço L; Brandão R; Ugurel S; Futschik M; Link W; et al. 2015. "TRIB2 as a biomarker for diagnosis and progression of melanoma.". Biochemical Society Transactions, 43: 1085-1088.
Wolfgang Link. 2015. "Molecular Inhibitors in Targeted Therapy". Molecular inhibitors in targeted therapy, 1 (1).
Cautain, B.; de Pedro, N.; Reyes, F.; Link, W.. 2015. Image-based identification of nuclear export inhibitors from natural products. Vol. 1270.
Cautain, B.; Hill, R.; De Pedro, N.; Link, W.. 2015. "Components and regulation of nuclear transport processes". FEBS Journal, 282 (3): 445-462.
Ferreira, B.I.; Hill, R.; Link, W.. 2015. "Caught in the crosshairs: Targeted drugs and personalized medicine". Cancer Journal (United States), 21 (6): 441-447.
Ferreira BI; Hill R; Link W. 2015. "Special Review: Caught in the Crosshairs: Targeted Drugs and Personalized Medicine.".
Tarrado-Castellarnau, Miriam; Cortes, Roldan; Zanuy, Miriam; Tarrago-Celada, Josep; Polat, Ibrahim H.; Hill, Richard; Fan, Teresa W. M.; Link, Wolfgang; Cascante, Marta. 2015. "Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition".
Baptista, Inês do Carmo Viegas. 2015. "Characterization of TRIB2 following PI3K inhibition". Mestrado.
Link, Wolfgang. 2015. Components and regulation of nuclear transport processes.
Link, Wolfgang. 2015. International Manual of Oncology Practice.
Wolfgang Link. 2015. Anti-cancer Drugs: Discovery, Development and Therapy.
Hill, R.; Cautain, B.; De Pedro, N.; Link, W.. 2014. "Targeting nucleocytoplasmic transport in cancer therapy". Oncotarget, 5 (1): 11-28.
Mori, Mattia; Vignaroli, Giulia; Cau, Ylenia; Dinic, Jelena; Hill, Richard; Rossi, Matteo; Colecchia, David; et al. 2014. "Discovery of 14-3-3 Protein- Protein Interaction Inhibitors that Sensitize Multidrug- Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693". Chemmedchem, 9 (5): 973-983.
Colaço, Laura Guerreiro. 2014. "Investigating the role and function of Tribbles 2 (TRIB2) in drug resistance within cancer". Mestrado.
Hill, Richard; Kalathur, Ravi Kiran Reddy; Callejas, Sergio; Colaço, Laura; Brandão, Ricardo; Serelde, Beatriz; Cebriá, Antonio; et al. 2014. "A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes". Breast Cancer Research, 16 (6).
Cortés, Roldán; Tarrado-Castellarnau, Míriam; Talancón, Daniel; López, Concepción; Link, Wolfgang; Ruiz, Daniel; Centelles, Josep Joan; Quirante, Josefina; Cascante, Marta. 2014. "A novel cyclometallated Pt(ii)–ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation". Metallomics, 6 (3).
Link Wolfgang; Madureira Patricia; Hill Richard. 2013. "Identifying new targets for personalized medicine". eLS. John Wiley & Sons, Ltd: Chichester.
Granda, T.G.; Cebrián, D.; Martínez, S.; Anguita, P.V.; López, E.C.; Link, W.; Merino, T.; et al. 2013. "Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases". Investigational New Drugs, 31 (1): 66-76.
Evensen, L.; Link, W.; Lorens, J.B.. 2013. "Image-based high-throughput screening for inhibitors of angiogenesis.". Methods in molecular biology (Clifton, N.J.), 931: 139-151.
Zanella, F.; dos Santos, N.R.; Link, W.. 2013. "Moving to the Core: Spatiotemporal analysis of forkhead Box O (FOXO) and nuclear factor-¿B (NF-¿B) nuclear translocation". Traffic, 14 (3): 247-258.
Cautain, Bastien; de Pedro, Nuria; Murillo Garzón, Virginia; Muñoz de Escalona, María; González Menéndez, Victor; Tormo, José R.; Martin, Jesús; et al. 2013. "High-Content Screening of Natural Products Reveals Novel Nuclear Export Inhibitors". Journal of Biomolecular Screening, 19 (1): 57-65.
Evensen, L.; Link, W.; Lorens, J.B.. 2012. Image-based high-throughput screening for inhibitors of angiogenesis. Vol. 931.
Wolfgang Link. 2012. "Nuclear accumulation of ß-catenin and forkhead box O3a in colon cancer: Dangerous liaison". World Journal of Biological Chemistry, 3 (9): 175-175.
Kauselmann, G.; Dopazo, A.; Link, W.. 2012. "Identification of disease-relevant genes for molecularly-targeted drug discovery". Current Cancer Drug Targets, 12 (1): 1-13.
Martínez González, S.; Hernández, A.I.; Varela, C.; Rodríguez-Arístegui, S.; Lorenzo, M.; Rodríguez, A.; Rivero, V.; et al. 2012. "Identification of ETP-46321, a potent and orally bioavailable PI3K a, d inhibitor". Bioorganic and Medicinal Chemistry Letters, 22 (10): 3460-3466.
Martinez Gonzalez, Sonia; Isabel Hernandez, Ana; Varela, Carmen; Rodriguez-Aristegui, Sonsoles; Maria Alvarez, Rosa; Belen Garcia, Ana; Lorenzo, Milagros; et al. 2012. "Imidazo 1,2-a pyrazines as novel PI3K inhibitors". Bioorganic & Medicinal Chemistry Letters, 22 (5): 1874-1878.
Martinez Gonzalez, Sonia; Isabel Hernandez, Ana; Varela, Carmen; Lorenzo, Milagros; Ramos-Lima, Francisco; Cendon, Elena; Cebrian, David; et al. 2012. "Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR". Bioorganic & Medicinal Chemistry Letters, 22 (16): 5208-5214.
Link, Wolfgang; Pastor J. F.. 2012. "New amino-imidazolothiadiazole compound useful for treating e.g. cancer, cardiovascular disease, viral infection, inflammation, neurological disorder, bone disorder, atherosclerosis, pulmonary fibrosisrestenosis, stroke, diabetes ". Concedida/Emitida.
Link, W.. 2011. "Editorial". Current Drug Targets, 12 (9): 1232-1234.
Link, Wolfgang. 2011. "Context-dependent therapeutic potential of FOXO proteins in oral squamous cell carcinoma". Oral Oncology, 47 (4): 229-230.
Hung, Mien-Chie; Link, Wolfgang. 2011. "Protein localization in disease and therapy". Journal of Cell Science, 124 (20): 3381-3392.
Zanella, F.; Link, W.; Carnero, A.. 2010. "Understanding FOXO, new views on old transcription factors". Current Cancer Drug Targets, 10 (2): 135-146.
Evensen, Lasse; Micklem, David R.; Link, Wolfgang; Lorens, James B.. 2010. "A Novel Imaging-based High-throughput Screening Approach to Anti-angiogenic Drug Discovery". Cytometry Part a, 77A (1): 41-51.
Pastor, J.; Martinez, S.; Alvarez, R. M.; Varela, C.; Hernandez, A. I.; Rodriguez, S.; Oyarzabal, J.; et al. 2010. "Amino-alkyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K". Ejc Supplements, 8 (7): 62-62.
Zanella, F.; Renner, O.; Garcia, B.; Callejas, S.; Dopazo, A.; Peregrina, S.; Carnero, A.; Link, W.. 2010. "Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells". Oncogene, 29 (20): 2973-2982.
Evensen, Lasse; Link, Wolfgang; Lorens, James B.. 2010. "Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery". Current Pharmaceutical Design, 16 (35): 3958-3963.
Rabal, Obdulia; Link, Wolfgang; Serelde, Beatriz G.; Bischoff, James R.; Oyarzabal, Julen. 2010. "An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries". Molecular Biosystems, 6 (4): 711-720.
Zanella, Fabian; Lorens, James B.; Link, Wolfgang. 2010. "High content screening: seeing is believing". Trends in Biotechnology, 28 (5): 237-245.
Link, W.. 2010. Finding novel targets for anticancer therapy.
2010. exCELLerate S.L.. Image-based Drug Discovery.
Link, W.. 2009. "Exploring the biological space of FOXO regulation: discovery of therapeutic targets and small molecule inhibitors for anticancer therapy". New Biotechnology, 25: S3-S3.
Zanella, Fabian; Rosado, Aranzazu; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. 2009. "Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators". Bmc Cell Biology, 10.
Link, Wolfgang; Oyarzabal, Julen; Serelde, Beatriz G.; Isabel Albarran, Maria; Rabal, Obdulia; Cebria, Antonio; Alfonso, Patricia; et al. 2009. "Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases". Journal of Biological Chemistry, 284 (41): 28392-28400.
Carnero, Amancio; Blanco-Aparicio, Carmen; Renner, Oliver; Link, Wolfgang; Leal, Juan F. M.. 2008. "The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications". Current Cancer Drug Targets, 8 (3): 187-198.
Rosado, Aranzazu; Zanella, Fabian; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. 2008. "A Dual-Color Fluorescence-Based Platform to Identify Selective Inhibitors of Akt Signaling". Plos One, 3 (3).
Zanella, Fabian; Rosado, Aranzazu; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. 2008. "Chemical Genetic Analysis of FOXO Nuclear-Cytoplasmic Shuttling by Using Image-Based Cell Screening". Chembiochem, 9 (14): 2229-2237.
Guijarro, Maria V.; Link, Wolfgang; Rosado, Aranzazu; Leal, Juan F. M.; Carnero, Amancio. 2007. "MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation". Carcinogenesis, 28 (12): 2443-2450.
Liebel, Urban; Link, Wolfgang. 2007. "Meeting report: trends and challenges in high content analysis.". Biotechnology journal, 2 (8): 938-40.
Zanella, Fabian; Rosado, Aranzazu; Blanco, Fernando; Henderson, Beric R.; Carnero, Amancio; Link, Wolfgang. 2007. "An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays". Assay and Drug Development Technologies, 5 (3): 333-341.
Link, W; Rosado, A; Fominaya, J; Thomas, JE; Carnero, A. 2005. "Membrane localization of all class IPI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt". Journal of Cellular Biochemistry, 95 (5): 979-989.
Link, WA; Ledo, F; Torres, B; Palczewska, M; Madsen, TM; Savignac, M; Albar, JP; Mellstrom, B; Naranjo, JR. 2004. "Day-night changes in downstream regulatory element antagonist modulator/potassium channel interacting protein activity contribute to circadian gene expression in pineal gland". Journal of Neuroscience, 24 (23): 5346-5355.
Mellstrom, Britt; Torres, Begona; Link, Wolfgang A; Naranjo, Jose R. 2004. "The BDNF gene: exemplifying complexity in Ca2+ -dependent gene expression.". Critical reviews in neurobiology, 16 (1-2): 43-9.
Moneo, V; Guijarro, MD; Link, W; Carnero, A. 2003. "Overexpression of cyclin D1 inhibits TNF-induced growth arrest". Journal of Cellular Biochemistry, 89 (3): 484-499.
Carnero, A.; Blanco, C.; Blanco, F.; Castro, M.E.; Guijarro, M.V.; Fominaya, J.; Link, W.; et al. 2003. "Exploring cellular senescence as a tumor suppressor mechanism". Clinical and Translational Oncology, 5 (5): 249-265.
Link, Wolfgang. 2003. "Caenorhabditis parkin gene and transgenic nematodes for use as Parkinson's disease models and for drug screening". Concedida/Emitida.
Sanz, C; Mellstrom, B; Link, WA; Naranjo, JR; Fernandez-Luna, JL. 2001. "Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic hrk gene in hematopoietic progenitor cells". Embo Journal, 20 (9): 2286-2292.
Ledo, F; Carrion, AM; Link, WA; Mellstrom, B; Naranjo, JR. 2000. "DREAM-alpha CREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription". Molecular and Cellular Biology, 20 (24): 9120-9126.
Link, WA; Kauselmann, G; Mellstrom, B; Kuhl, D; Naranjo, JR. 2000. "Induction of glycerol phosphate dehydrogenase gene expression during seizure and analgesia". Journal of Neurochemistry, 75 (4): 1419-1428.
Ledo, F; Link, WA; Carrion, AM; Echeverria, V; Mellstrom, B; Naranjo, JR. 2000. "The DREAM-DRE interaction: key nucleotides and dominant negative mutants". Biochimica Et Biophysica Acta-Molecular Cell Research, 1498 (2-3): 162-168.
Link, Wolfgang. 2000. "Calcium-dependent transcriptional regulator DREAM and its cDNA and methods for drug screening". Concedida/Emitida.
Carrión, A.M.; Link, W.A.; Ledo, F.; Mellström, B.; Naranjo, J.R.. 1999. "DREAM is a Ca<sup>2+</sup>-regulated transcriptional repressor". Nature, 398 (6722): 80-84.
Carrion, A.M.; Taylor, J.S.; Link, W.; Morcuende, S.; Mellsrtrom, B.; Naranjo, J.R.. 1996. "Early gene induction and spinal cord function". DOLOR, 11 (1): 22-24.;partnerID=MN8TOARS
LINK, W; KONIETZKO, U; KAUSELMANN, G; KRUG, M; SCHWANKE, B; FREY, U; KUHL, D. 1995. "SOMATODENDRITIC EXPRESSION OF AN IMMEDIATE-EARLY GENE IS REGULATED BY SYNAPTIC ACTIVITY". Proceedings of the National Academy of Sciences of the United States of America, 92 (12): 5734-5738.